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Background:  HIV-exposed  uninfected  infants  have  increased  infection  risk  and  mortality  compared  to
HIV-unexposed  infants.  HIV-exposed  infants  may  be at  increased  risk  of  invasive  GBS  disease  due to
reduced  maternal  antibody  against  GBS.
Methods: We  quantiﬁed  antibodies  that  bind  to  the surface  of  whole  Group  B Streptococcus  (GBS) of
serotypes  Ia,  Ib,  II, III and  V  using  novel  ﬂow  cytometry  assays  in  South  African  HIV-infected  and  non-
infected  mothers  and  their  uninfected  infants.  Antibody-mediated  complement  C3b/iC3b  deposition  onto
GBS of  these  serotypes  was  also  quantiﬁed  by a novel  ﬂow  cytometry  assay.
Results: Geometric  mean  concentration  (GMC)  of  both  surface-binding  anti-GBS  antibody  and  antibody-
mediated  complement  deposition  onto  GBS  were reduced  in  HIV-infected  women  (n = 46)  compared  to
HIV-uninfected  women  (n  =  58)  for ST1a  (surface-binding:  19.3 vs  29.3;  p  =  0.003;  complement  depo-
sition:  2.9  vs  5.3  SU/mL;  p = 0.003),  STIb  (24.9  vs  47.6;  p =  0.003;  2.6 vs  4.9  SU/mL;  p =  0.003),  STII (19.8
vs  50.0;  p = 0.001;  3.1 vs  6.2 SU/mL; p = 0.001),  STIII  (27.8  vs  60.1;  p = 0.001;  2.8 vs  5.3 SU/mL;  p =  0.001)
and  STV (121.9  vs  185.6 SU/mL;  p  <  0.001)  and  in  their infants  for STIa  (complement  deposition  9.4 vs
27.0  SU/mL;  p = 0.02),  STIb  (13.4  vs  24.5  SU/mL;  p = 0.02),  STII (14.6  vs  42.7 SU/mL;  p  = 0.03),  STIII  (26.6 vs
62.7  SU/mL;  p = 0.03)  and  STV  (90.4 vs  165.8  SU/mL;  p = 0.04).  Median  transplacental  transfer  of antibody
from  HIV-infected  women  to their  infants  was reduced  compared  to HIV-uninfected  women  for  GBS
serotypes  II (0.42  [IQR  0.22–0.59]  vs 1.0  SU/mL  [0.42–1.66];  p < 0.001),  III (0.54  [0.31–1.03]  vs  0.95  SU/mL
[0.42–3.05],  p  =  0.05)  and V  (0.51  [0.28–0.79]  vs  0.75  SU/mL  [0.26–2.9],  p =  0.04).  The differences  between
infants  remained  signiﬁcant  at 16  weeks  of age.
Conclusions:  Maternal  HIV  infection  was  associated  with  lower  anti-GBS  surface  binding  antibody  con-
centration  and  antibody-mediated  C3b/iC3b  deposition  onto  GBS  bacteria  of serotypes  Ia,  Ib,  II,  III and  V.
This  may  render  these  infants  more  susceptible  to  early  and  late onset  GBS  disease.
Crown  Copyright  © 2014  Published  by  Elsevier  Ltd.  This  is  an open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The increasing numbers of HIV-exposed infants who remain
uninfected is testament to the success of prevention of mother-to-
child transmission programs in resource-poor settings in the face
 Preliminary data was presented at the European Society of Infectious Diseases
meeting May  2014, Dublin, Ireland.
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of a high disease burden [1]. Nevertheless, this group of infants
appears to suffer from increased rates of lower respiratory tract
infection and meningitis compared to HIV-unexposed infants and
up to 4-fold higher mortality in the ﬁrst year of life [2–4]. Strepto-
coccus agalactiae (group B streptococcus, GBS) is a leading cause of
neonatal pneumonia, sepsis and meningitis in many countries and
ﬁve serotypes (Ia, Ib, II, III and V) account for the majority of disease
[5]. Published data show that not only is GBS carriage increased
in HIV-infected pregnant women  compared with HIV-uninfected
mothers [6], but that HIV-exposed, uninfected infants also appear
to have an increased risk of late-onset GBS disease compared to
HIV-unexposed infants [7].
http://dx.doi.org/10.1016/j.vaccine.2014.12.025
0264-410X/Crown Copyright © 2014 Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Prevention of GBS infection in infants and adults through immu-
nization is a theoretically attainable goal. Maternal transfer of
antibodies is thought to prevent newborn GBS disease [8] and
GBS vaccines offer the potential to prevent disease in low-income
settings where prenatal screening and intrapartum antibiotics are
generally not feasible. A number of studies have demonstrated
an association between the risk of developing invasive GBS dis-
ease in the newborn and maternal anti-capsular antibody levels
[9–12] with opsonophagocytosis the likely effector mechanism
[13–15]. However, maternal HIV status can inﬂuence the efﬁ-
ciency of transplacental antibody transfer, resulting in reduced
maternally-derived speciﬁc antibody concentration in the infant,
even where the infant is subsequently HIV uninfected [16–19].
Data regarding the persistence of anti-GBS antibodies in popula-
tions with high HIV-prevalence and their function in vitro would
provide insight into their protective potential in different popula-
tions. Thus our objective was to determine the association between
maternal HIV infection status and total IgG binding to the surface of
GBS bacteria of serotypes Ia, Ib, II, II and V and antibody-mediated
deposition of C3b/iC3b onto the surface of these GBS strains as a
potential surrogate for opsonophagocytosis in sera obtained from
mothers and infants.
2. Methods
2.1. Study setting, eligibility and study measures
Samples were collected from mothers and infants enrolled in
a cohort study investigating the inﬂuence of maternal HIV and
mycobacterial sensitization on infant immune responses to BCG
vaccination carried out between 2009 and 2011 [20]. In brief, 109
pregnant women presenting to a Community Health Center in
Khayelitsha, Western Cape Province, South Africa who  delivered
a healthy infant over 37 weeks gestation, weighing over 2.5 kg,
knew the result of their HIV test and were willing to provide
written informed consent for themselves and their infants were
recruited to the original study. The subset represented all moth-
ers/infants with available samples. A venous blood sample was
collected from the mother and infant within 24 h of delivery.
All infants had a further venous blood sample collected at 16
weeks. HIV-exposed infants had an HIV polymerase chain reaction
(Amplicor HIV-a DNA kit, version 1.5; Roche Molecular Systems
Inc., Branchburg, NJ) performed at ages 4 and 16 weeks. The study
was approved by the Universities of Cape Town (382/2008) and
Stellenbosch (N08/10/278), South Africa, and the National Health
Service Research Ethics Committee, England (07/H0720/178).
In 2009, the HIV prevalence among women attending antenatal
clinics in the area was 31% [21]. During the study period, the Pre-
vention of Mother to Child Transmission program consisted of dual
therapy for mothers and infants, starting with the administration
of zidovudine at 28 or more weeks’ gestation, then zidovudine for 1
month to the infant and a single dose of nevirapine to both mother
and infant. Mothers were eligible for highly active antiretroviral
treatment if their CD4 count was less than 200 cells/L. Exclu-
sive infant feeding options were encouraged and mothers were
provided with free formula for 6 months if they chose exclusive
formula feeding.
2.2. Laboratory assays
The reproducibility of the assays was assessed between three
different days and between three different operators with a panel
of 18 sera. The assays had a coefﬁcient of variation of less than
30%. Controls used were rabbit polyclonal sera (SSI) raised against
serotypes Ia, Ib, II, III & V, and normal human donor sera.
2.2.1. GBS isolates and growth conditions
Group B Streptococcus isolates used in this study were
H092040676 (Serotype Ia), H090820125 (Serotype Ib),
H090320548 (Serotype II), H092120162 (Serotype III) and
H091780506 (Serotype V), which were kindly provided by
Professor Androulla Efstratiou, Public Health England, Colindale.
Strains are subsequently referred to by their serotype.
GBS isolates used in the antibody surface binding and comple-
ment deposition assays were grown in Todd Hewitt broth at 37 ◦C
with shaking (200 rpm). Once OD600nm 1.0 was reached, cultures
were centrifuged at 3060 × g for 5 min  to pellet the bacteria. The
pellet was  re-suspended in the same volume of phosphate buffered
saline (PBS, pH 7.4, Severn Biotech, UK) containing 2% formalde-
hyde and incubated at room temperature for 1 h. Bacteria were
then washed in PBS by three rounds of centrifugation at 3060 × g
for 5 min  and resuspended. The ﬁnal cell pellet was resuspended in
1 mL  PBS, which was stored at 4 ◦C before use.
2.2.2. Sample preparation for antibody surface binding assay
Deposition of anti-GBS antibody onto the surface of whole
GBS bacteria was  measured on formaldehyde-ﬁxed GBS using a
ﬂow cytometric assay performed in 96-well microtitration plates.
Brieﬂy, 2 L of each test serum was  added to 198 L of serotype Ia,
Ib, II, III or V GBS bacteria at 5.14 × 107 CFU/mL in blocking buffer
(1% BSA in PBS). This was incubated at 25 ◦C for 30 min with shaking
(900 rpm), then pelleted. Supernatant was removed and the pel-
let washed twice with 200 L of blocking buffer. Alexa Fluor® 488
Goat Anti-Human IgG (H&L) (Life Technologies) (1:500) in blocking
buffer was added and samples incubated for 20 min  at 4 ◦C, before
being washed twice more with blocking buffer.
2.2.3. Sample preparation for antibody-mediated complement
C3b/iC3b deposition assay
Antibody-mediated C3b/iC3b deposition on the surface of whole
GBS bacteria was measured on the surface of formaldehyde-ﬁxed
GBS using a ﬂow cytometric assay performed in 96-well microtitra-
tion plates. Brieﬂy, 35 L serotype Ia, Ib, II, III and V GBS bacteria at
5.14 × 107 CFU/mL in blocking buffer (1% BSA in PBS) were added
to 10 L IgG-depleted human complement [22] and 5 L of each
test serum. Plates were incubated for 7.5 min  at 37 ◦C with shak-
ing (900 rpm) then pelleted. Supernatant was removed and the
pellet washed once with 200 L blocking buffer. Samples were
resuspended in 200 L blocking buffer containing 1:500 sheep anti-
human C3c FITC (Abcam) and incubated as for the surface binding
assay.
2.2.4. Sample acquisition
Assays were analyzed using a Beckman Coulter Cyan ﬂow
cytometer equipped with a Cytek 96-well microtitre plate reader.
Protocols were initially set-up to analyze proﬁles of bacterial events
using bacteria-only control samples and the bacteria identiﬁed on
the cytometer by the forward scatter (FS), measuring the size of the
cell, and side scatter (SS), the granularity and internal structural
complexity. An analysis ‘gate’ was  drawn around the population
of interest (single and diplococci) and a relevant histogram plot
created to analyze the ﬂuorescence of the bacterial population.
For each sample, 10,000 individual events were analyzed for ﬂu-
orescence and a horizontal gate was  drawn to include 10% of the
‘no antibody’ control population. A ﬂuorescence index (FI) was
calculated for each sample, which involved the multiplication of
the percentage of bacteria in the horizontal gate (%-gated), by the
mean ﬂuorescence of that population (X-mean). The ﬁnal result
for each test was expressed as the average FI of duplicate test
samples minus the average FI of the bacteria and conjugate-only
control. A standard unit (SU) measurement for each serum sam-
ple was then calculated by comparing to the serum FI response
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obtained with the positive control serum for each serotype which
was given an arbitrary value of 1000 (kind gift from Professor
Carol Baker, Baylor College of Medicine, Texas) to give a result in
SU/mL.
2.3. Data management and statistical analysis
Sample size was determined for the cohort study; this sub-study
had 80% power (p = 0.05) to investigate differences between anti-
body concentrations in HIV-exposed and HIV-unexposed infants
of at least 30% with the pre-speciﬁed hypothesis that the con-
centrations would be lower in HIV-exposed infants. This assay is
currently being formally compared with ELISA and opsonophago-
cytosis uptake assays in another study.
Statistical analyzes were completed using STATA version 12
(StataCorp 2013, La Jolla, CA) and GraphPad Prism version 6.0
(GraphPad Software Inc., La Jolla, CA). Due to the skewed distribu-
tion of the anti-GBS antibody concentrations, log transformations
were required to conform to regression assumptions. A paired t-test
was used to determine any difference in anti-GBS-antibody con-
centrations to each GBS serotype between birth and at 16 weeks.
Comparison of infant anti-GBS antibody concentrations by mater-
nal HIV status was calculated using the Wilcoxon rank sum test.
Correlation of infant anti-GBS antibody concentration to each GBS
serotype at birth and at 16 weeks was assessed using Spearman
correlation. Multiple linear regression was used to ascertain the
relationship between infant anti-GBS antibody concentration to
each GBS serotype and the covariates of maternal age, infant sex
and maternal HIV. In addition, multiple linear regression was used
to explore the relationship between maternal anti-GBS antibody
concentration to each serotype and the covariates maternal age,
maternal HIV status. Placental transfer was deﬁned as the ratio
of infant-to-mother anti-GBS IgG concentration at birth. Missing
data were excluded from analysis. Decline in antibody concentra-
tion between birth and 16 weeks was calculated using ratio of
means.
3. Results
3.1. Participant characteristics
Samples were analyzed from 104 women (46 (44%) HIV-infected
and 58 (56%) HIV-uninfected women) and from 100 infants born to
this group of women (46 (46%) HIV-exposed and 54 (54%) HIV-
unexposed infants). One mother–infant pair was  excluded from
the ﬁnal analysis because HIV-infection in the infant was  detected
at 4 weeks of age and the infant was referred for rapid initiation
of antiretroviral treatment. All other infants born to HIV-infected
mothers were HIV-uninfected. All infants were born after 37 weeks
gestation. Follow-up samples at 16 weeks were available for 93
infants (93%; 38 HIV-exposed and 55 HIV-unexposed) at a mean
postnatal age of 16.4 weeks (SD = 1.7).
All HIV-infected women chose exclusive formula replacement
feeding. The median (IQR) CD4 count among the HIV-infected
women was 411.5 (293.9–604.0) cells/L and the median (IQR)
viral load was 800 (357–6000) copies/mL Seven women had CD4
counts of less than 200 cells/L; three of these were taking
highly active antiretroviral treatment at enrollment and four were
referred to commence highly active antiretroviral treatment fol-
lowing delivery. Further characteristics of the study cohort have
been described previously [20]. At the time of the study, local
GBS disease incidence in Cape Town was reported at 0.67/1000
live births in a population with 24% of these infants being HIV-
uninfected, born to HIV-infected mothers [23].
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Fig. 1. Reverse cumulative distribution curve of maternal anti-GBS IgG surface bind-
ing by serotype concentrations (SU/mL). Curve demonstrates the percentage of the
total population with each antibody concentration for each of the ﬁve GBS serotypes.
ST,  serotype; SU/mL, standard units/mL
3.2. Maternal anti-GBS-antibody to GBS serotypes Ia, Ib, II, III and
V
All maternal sera had measurable geometric mean concentra-
tions (GMC) of antibody to at least one serotype. The distribution
of mothers’ antibodies that bound to the surface of GBS serotypes
Ia, Ib, II, III and V is shown in Fig. 1. The predominant surface bind-
ing anti-GBS-antibody was  against serotype V, followed by II, III, Ib
and Ia (Fig. 1).
Women  with HIV infection had signiﬁcantly lower GMC  anti-
body concentrations to all ﬁve serotypes at delivery compared to
HIV-uninfected women (Fig. 2 and Table 1). There were no asso-
ciations between CD4 count and viral load on anti-GBS antibody
concentration by serotype in HIV-infected women.
The concentrations of antibody-mediated complement
C3b/iC3b deposition by GBS serotype are shown in Table 2.
The GMC  of antibody-mediated C3b/iC3b deposition was  signiﬁ-
cantly greater in HIV-uninfected than HIV-infected women  for all
serotypes. The GMC  of antibody-mediated C3b/iC3b deposition
ranged from 4.9 SU/mL (serotype III) to 6.17 SU/mL  (serotype V)
in HIV-uninfected women  and from 2.6 SU/mL (serotype Ib) to
3.4 SU/mL (serotype V) in HIV-infected women.
3.3. Association of maternal HIV infection with placental transfer
of anti-GBS antibody
There was a positive correlation between paired maternal and
infant surface binding antibody concentrations for all serotypes (Ia,
r2 = 0.63, p < 0.001; Ib, r2 = 0.71, p < 0.001; II, r2 = 0.17, p < 0.001; III,
r2 = 0.35, p < 0.001; V, r2 = 0.16, p < 0.001). HIV-infected women had
signiﬁcant reductions in placental transfer of anti-GBS serotypes II
and V compared with HIV-uninfected women (Table 3). There was
no association between CD4 count or viral load on transplacental
transfer ratios.
3.4. Infant anti-GBS-antibody by serotype at birth to GBS
serotypes Ia, Ib, II, III and V
HIV-exposed uninfected infants had signiﬁcantly lower GMCs
of anti-GBS surface binding antibodies to all serotypes than unex-
posed infants (Fig. 3 and Table 1). In a multiple regression model
maternal HIV-status remained signiﬁcant (p < 0.05).
However, there were no signiﬁcant associations found between
infant anti-GBS-antibody concentrations to each serotype and
maternal age or infant sex.
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Fig. 2. Maternal anti-GBS surface binding IgG to GBS serotypes Ia, Ib, II, III and V concentrations at delivery (SU/mL). ST indicates GBS serotype. HIV indicates human
immunodeﬁciency virus. Horizontal lines indicate GMC  response.
Table 1
Geometric mean surface binding antibody concentrations (95% conﬁdence intervals) in HIV-infected and HIV-uninfected mothers and their infants at birth and at 16 weeks
of  age.
STIa STIb STII STIII STV
HIV+ mother 19.3 (12.7–29.3) 24.9 (19.6–31.6) 21.8 (13.4–35.7) 27.8 (15.9–48.6) 121.9 (88.0–169.0)
HIV−  mother 37.0 (24.8–55.2) 47.6 (33.3–68.1) 50.0 (28.7–87.0) 60.1 (36.0–100.5) 185.6 (126.4–272.4)
HIV-exposed infants (birth) 9.4 (6.1–14.5) 13.4 (9.6–18.7) 14.6 (8.1–26.3) 26.6 (17.8–39.8) 90.4 (61.16–133.6)
HIV-unexposed infants (birth) 27.0 (16.5–44.3) 24.5 (16.4–36.5) 42.7 (23.4–77.8) 62.7 (38.1–103.1) 165.8 (112.0–245.4)
HIV-exposed infants (16 w) 7.0 (3.8–13.0) 8.7 (6.3–12.1) 17.6 (8.5–36.3) 48.0 (28.3–81.3) 68.54 (38.0–123.6)
HIV-unexposed infants (16 w)  21.6 (13.6–34.2) 14.9 (10.6–21.1) 68.3 (38.8–120.3) 97.4 (63.0–150.7) 180.2 (106.3–305.4)
STIa, GBS serotype Ia; STIb, GBS serotype Ib; STII, GBS serotype STII; STIII, GBS serotype III; STV, GBS serotype V; HIV+, HIV infected; HIV−, HIV uninfected; 16 w,  16 weeks of
age.
Table  2
Geometric mean concentration of antibody-mediated C3b/iC3b deposition (95% conﬁdence intervals) on GBS serotypes Ia, Ib, II, III and V in HIV-infected and HIV-uninfected
mothers and their infants at birth.
STIa p value STIb p value STII p value STIII p value STV p value
HIV+ mother 2.9 (2.3–3.6) 2.6 (1.9–3.2) 3.1 (2.4–3.9) 2.8 (2.2–3.6) 3.4 (2.8–4.2)
HIV−  mother 5.3 (4.6–6.2) 0.003 4.9 (4.2–5.4) 0.003 6.2 (5.6–6.8) 0.001 5.3 (4.5–6.2) 0.001 6.2 (4.9–6.9) <0.0001
HIV-unexposed infants 6.1 (5.9–6.3) 5.9 (4.6–6.2) 6.9 (5.6–7.2) 6.6 (6.4–6.7) 6.3 (5.8–6.9)
HIV-exposed infants 3.8 (3.0–4.8) 0.02 3.1 (3.0–4.1) 0.02 4.2 (3.9–4.9) 0.02 3.9 (3.1–5.0) 0.03 4.2 (3.3–5.4) 0.04
STIa, GBS serotype Ia; STIb, GBS serotype Ib; STII, GBS serotype STII; STIII, GBS serotype III; STV, GBS serotype V; HIV+, HIV infected; HIV−, HIV uninfected.
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Table  3
Inﬂuence of maternal HIV-infection on transplacental transfer of anti-GBS surface binding antibody to GBS serotypes Ia, Ib, II, III and V.
GBS serotype HIV-infected mothers: infants (IQR) HIV-uninfected mothers: infants (IQR) % Reduction in HIV-infected p value
STIa 0.66 (0.34–0.99) 0.6 (0.39–0.96) 0% 0.86
STIb  0.48 (0.17–0.88) 0.52 (0.32–0.78) 8% 0.48
STII  0.42 (0.22–0.59) 1.0 (0.42–1.66) 58% <0.001
STIII  0.54 (0.31–1.03) 0.95 (0.4–3.05) 43% 0.05
STV  0.51 (0.28–0.79) 0.75 (0.26–2.9) 32% 0.04
STIa, GBS serotype Ia; STIb, GBS serotype Ib; STII, GBS serotype STII; STIII, GBS serotype III; STV, GBS serotype V; IQR, interquartile range; HIV+, HIV infected, HIV−, HIV
uninfected; 16 w,  16 weeks of age.
Signiﬁcantly lower GMC  of antibody-mediated C3b/iC3b depo-
sition was noted amongst HIV-exposed infants compared to
HIV-unexposed infants for all serotypes (Table 2). Notably, the GMC
of antibody-mediated C3b/iC3b deposition was higher in infants
than in their mothers for all serotypes.
3.5. Infant anti-GBS antibody at 16 weeks of age
Anti-GBS surface binding antibody GMCs remained signiﬁcantly
lower at 16 weeks in HIV-exposed uninfected infants compared to
unexposed infants for all serotypes (Table 1). HIV-exposed infants
had signiﬁcantly slower median rate of antibody decline com-
pared to HIV-unexposed infants at 16 weeks compared to birth to
STII (ratio of decline 1.03 [IQR −0.35 to 4.6] vs 0.21 SU/mL [−0.62
to 0.54], p = 0.04) and STIII (1.53 [−0.21 to 5.36] vs −0.09 SU/mL
(−0.60 to 0.93), p = 0.03) but not to ST1a (−0.12 [IQR −0.64 to
0.13] vs −0.04 [−0.39 to 0.45]), ST1b (−0.52 [−0.65 to 0.46]
vs −0.36 [−0.18 to 0.74]) or STV (−0.40 [−0.61 to 2.9] vs 0.14
[−0.52 to 2.7]).
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Fig. 3. Infant anti-GBS IgG serotype speciﬁc antibody concentrations (SU/mL). ST indicates GBS serotype. HIV indicates human immunodeﬁciency virus. Horizontal lines
indicate GMC.
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4. Discussion
Our ﬁndings demonstrate that total surface binding and func-
tional maternal antibody concentration to each of the GBS
serotypes (Ia, Ib, II, III and V) is lower at delivery in HIV-infected
women compared to their HIV-uninfected peers. Further, for three
of the ﬁve serotypes (II, III, V) the transplacental transfer ratio
was signiﬁcantly lower from HIV-infected women to their unin-
fected infants. It follows therefore that infants born to HIV-infected
women had lower anti-GBS surface binding antibody concentra-
tions at birth for all serotypes; this difference was still evident at
16 weeks of age. The implication of our ﬁndings is that HIV-exposed
infants may  be more vulnerable to early and late onset GBS disease
than infants born to HIV-uninfected mothers.
Rectovaginal colonization with GBS is more frequent in HIV-
infected women compared to HIV-uninfected women [6,24].
Maternal colonization is the major risk factor for infant acquisi-
tion at birth and for early onset GBS disease. Thus infants born
to HIV infected mothers may  have both increased susceptibility
and increased exposure. It is generally understood that mater-
nal colonization stimulates maternal immunity; thus the ﬁnding
of lower maternal antibody concentrations despite higher colo-
nization rates suggests impairment of anti-GBS-speciﬁc antibody
production. This is also seen with polysaccharide-speciﬁc antibody
production in HIV-infected adults, such as in pneumococcal dis-
ease [25]. The fact that HIV-infected women have higher rates of
GBS colonization than HIV-uninfected women may  mean that anti-
body production secondary to colonization with GBS is deﬁcient in
the context of maternal HIV-infection increasing the risk of invasive
GBS disease in HIV-exposed infants.
It is difﬁcult to correlate our anti-GBS antibody results with what
is known regarding maternal colonization and infant GBS disease in
this South African population. However, the highest concentrations
of antibodies in women at delivery were to STV and III bacteria. The
latter is consistent with the known predominance of STIII among
carried strains in South African women (37%) but STV is carried by
a minority of women (10%) [24,26]. In our cohort the lowest lev-
els of antibody were to STIa bacteria, which is consistent with an
increased incidence of disease due to this serotype [26]. Our ﬁnd-
ings may  suggest differences in the immune response to different
colonizing serotypes.
It is likely that lower maternal antibody concentrations and
altered transplacental transfer of antibody in HIV infection play a
role in the increased susceptibility to infectious diseases in infancy
[19,27], but there is a lack of data on the impact of maternal HIV
infection on neonatal infections in general, including GBS infec-
tions [28]. Infant anti-GBS surface binding antibody by serotype
remains lower at 16 weeks in HIV-exposed, uninfected infants,
who might therefore be more vulnerable to late onset GBS disease.
This corresponds to recent data from Cape Town which suggest
that 56% of GBS disease occurred after 7 days of life in a popula-
tion where one in four infants were HIV-exposed [23]. Apart from
the reduced passive immunity provided by maternal antibody in
the context of maternal HIV infection it might be that there are
differences in the immune response to infection of HIV-exposed,
uninfected infants secondary to in utero HIV exposure, as some data
suggest that these infants have altered lymphocyte differentiation
and function despite remaining HIV-uninfected [29,30]. However,
how this corresponds to clinical infection in the neonatal period is
not known.
Our ﬁndings are consistent with studies that demonstrate the
higher risk of infectious morbidity and mortality in HIV-exposed
infants compared to HIV-unexposed infants [31–33]. Recent South
African studies demonstrated a high prevalence of neonatal GBS
disease in a population with a high HIV burden [23,24,34]. A Study
from Malawi also demonstrated high rates of early and late onset
GBS infection in a population with high HIV prevalence [35]. In
contrast, one study from the USA did not ﬁnd evidence of increased
susceptibility to GBS infection in HIV-exposed, uninfected infants
suggesting either regional screening and treatment differences
for both HIV infection and GBS carriage or population-based dif-
ferences in late onset GBS disease that might be unrelated to
HIV-status [36].
Our study has some limitations. Firstly, we  did not assess col-
onization in the mothers participating in the study and thus were
unable to correlate antibody responses to maternal colonization.
Whilst no infant developed early or late onset sepsis or meningitis
during the study, our sample size was also too small to detect this
as a valid endpoint and this was  not the aim of the study.
The use of two novel ﬂow cytometric assays that quantify anti-
body binding to the surface of GBS bacteria and antibody-mediated
C3b/iC3b deposition on the bacterial surface may provide a more
complete assessment of antibody function than the measurement
of anti-polysaccharide IgG alone. However, the response measured
is not wholly serotype-speciﬁc as part of the antibody binding is
to cell wall proteins as well as the polysaccharide capsule. Despite
this, we see a serotype-speciﬁc response with a clear differentia-
tion between the distribution of antibody binding to the different
serotypes.
The potential of a trivalent maternal GBS vaccine encompass-
ing the major disease-causing serotypes (Ia, Ib, III) [8] to protect
against neonatal disease remains promising. However, it is vital
that ongoing evidence to support its use in vulnerable populations
with high HIV-prevalence is collected in order to support immu-
nization strategies in Sub-Saharan Africa.
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